written on 29.04.2014

OncoGenex sinks, sees prostate potential after custirsen failure


Bothell, Washington-based OncoGenex closed at $3.85 per share on 28 April versus $9.70 before the weekend. The company shed $86.1m of its value, bringing its market cap to $56.7m based on the first set of Phase III data for its lead drug candidate….